Lupin receives FDA approval for generic Topicort Topical Spray

Pharma major Lupin said that it has received final approval for its Desoximetasone Topical Spray, 0.25%, 30 ml, 50 ml, and 100 ml from the United States Food and Drug Administration (FDA) to market a generic version of Taro Pharmaceuticals U.S.A Inc.’s Topicort Topical Spray, 0.25%. “Lupin’s Desoximetasone Topical Spray, 0.25%, 30 ml, 50 ml, and 100 ml is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.’s Topicort Topical Spray, 0.25%. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older,” the company said in a filing to the Bombay Stock Exchange.

Desoximetasone Topical Spray, 0.25%, 30 ml, 50 ml, and 100 ml had annual sales of approximately USD 19.5 million in the US (IQVIA MATJanuary 2018). Meanwhile, shares of the company were trading at Rs 769.85 apiece, up 1 per cent from the previous close at 13:00 hours on BSE.

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: